Abiomed’s Impella CP Introducer* was recently FDA cleared1 , and is being released to users. It has a 14 French (F) sheath, which permits placement of the Impella CP’s pump (motor and housing). However, after the Impella CP pump is positioned in the ventricle, its smaller Impella 9 F catheter shaft remains in the introducer. … Continue reading “Single-Access with 14 F Impella Sheath Procedural Steps”
Dr. Flaherty presents a case review of an 85-year-old male who presented with unstable angina symptoms, multivessel coronary artery disease (CAD), severe PVD (right leg intermittent claudication), moderate-severe bioprosthetic aortic valve stenosis, and a depressed ejection fraction (35%). IMP-938
The 2020 Clinical Dossier: Protected PCI with Impella® is a collection of data and clinical evidence supporting the use of Impella in High-Risk Percutaneous procedures.
With Impella support in high-risk PCI, overall incidence of post-procedural AKI is significantly reduced relative to predicted risk
Sites participating in the National Cardiogenic Shock Initiative (CSI) have adopted the National CSI algorithm as the foundation for their treatment of AMI (STEMI & NSTEMI) patients who present in cardiogenic shock. Learn more at www.henryford.com/national-csi IMP-104-17 v2
Successful Implementation of Cardiogenic Shock Algorithm Dr. Salvatore Mannino discusses the cardiogenic shock algorithm used in his successful spoke and hub network. Dr. Mannino is director of the short-term mechanical circulatory support program at WellStar Health System, the largest healthcare system in Georgia. Starting in 2016, each hospital in the WellStar spoke and hub network … Continue reading “WellStar Hub and Spoke Cardiogenic Shock Treatment Network”
Jeffrey J. Popma, MD, presents the latest data from the PROTECT series clinical study